CCB
VVOS icon

Cutter & Co Brokerage’s Vivos Therapeutics VVOS Stock Holding History

Cutter & Co Brokerage’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,100
Closed -$140K – 172
2025
Q1 		$140K Buy
49,100
+11,000
+29% +$43.2K 0.03% 173
2024
Q4 		$163K Buy
+38,100
New +$127K 0.04% 187

Other funds holding VVOS

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cutter & Co Brokerage's VVOS Position: Q2 2025 in Review

Cutter & Co Brokerage sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 49,100 shares — an estimated $140K sold.

Cutter & Co Brokerage first reported a position in VVOS in Q4 2024 and held it in 2 quarters. The position peaked at $163K in Q4 2024. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

  • Cutter & Co Brokerage reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cutter & Co Brokerage sold 49,100 Vivos Therapeutics shares in Q2 2025, an estimated $140K.
  • Cutter & Co Brokerage first reported a position in Vivos Therapeutics in Q4 2024 and held it in 2 quarters.
  • Cutter & Co Brokerage's Vivos Therapeutics position peaked at $163K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on Cutter & Co Brokerage's 13F filing for Q2 2025.